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Abstract
Carcinoids are neuroendocrine tumours which may secrete hormones like gastrin, insulin, ACTH,
etc. Liver is a common site for metastasis of carcinoid origin and an unusual site for a primary
carcinoid tumour to arise.
We present the case of a 51-year-old Caucasian man with diarrhoea, weight loss, duodenum ulcers
and a liver mass in ultrasonography. A primary hepatic carcinoid tumour with a Zollinger Ellison
syndrome was diagnosed. Surgery resection was performed and the patient remained free of
symptoms two years after, with normalisation of gastrin levels.
Primary hepatic carcinoid tumour represents an uncommon diagnosis, based on radiological and
pathological features. The exclusion of different primary locations is necessary. Once associated with
a Zollinger Ellison syndrome, diagnose may be more complicated and challenging since only 7 cases
of hepatic carcinoids with gastrin secretion were reported in medical literature.
A review of medical literature is performed and diagnoses tools that should be used for an accurate
diagnosis and available treatment approaches are commented here.
Introduction
Gastrin is predominantly produced by G cells of the gastric
antrum and plays two major roles in the gastrointestinal
physiology: (i) stimulation of gastric acid secretion and
(ii) secondly as a trophic hormone for epithelial and
enterochromaffincellsgrowth[1,2].Therearemanycauses
of chronic gastrinemia and most of them are associated
with gastrin secreting tumours (gastrinomas and gastrin
secretingcarcinoidtumours).Other causesarerelationated
with high continuous antral pH (chronic atrophic gastritis,
truncal vagotomy without antrectomy, chronic antisecre-
tory treatment, etc). Gastrinomas are usually associated
with the Zollinger Ellison syndrome (ZES) which is
characterized by multiple peptic ulcers (most in the first
portion of duodenum) and severe diarrhoea with inflam-
matory, osmotic or malabsorptive features due to the
excessive acidification of the duodenum and the lower
small bowel [2].
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neuroendocrine system and usually secret hormones like
gastrin, chromogranin A, serotonin, ACTH, insulin, etc.
[3]. The majority arises within the gastrointestinal tract,
mostly in the appendix and terminal ileum [3], few within
other organs like bronchi. Liver is a common site for
metastasis of carcinoid origin and an unusual site for a
primary carcinoid tumour to arise.
Case presentation
A 51-year-old Caucasian man of Spanish nationality was
admitted to our department for diarrhoea. The symptoms
began 11 years ago and were intermittent and mostly
nocturnal. He worsened 3 months before admission with
exacerbation of number of deposition, abdominal pain
and weight loss. He was on PPI therapy on demand and at
high doses for pyrosis. He consumed no toxics. His
medical history was irrelevant and his physical examina-
tion was unremarkable except for the presence of a mass in
his left upper quadrant of abdomen. No palpable lymph
nodes and no splenomegaly were found.
A complete blood count revealedm i l dl e u k o c y t o s i s( l e u k o -
cytes 16.000, neutrophils 83%). Coagulation study and
biochemistry tests including liver, kidney and thyroid gland
function, iron metabolism and tumour markers presented
no remarkable alterations. The reactive C protein was of
42.7 mg/dl (normal: 0-5 mg/dl). Gastrin level was of
114 ng/ml (normal: 13-115 ng/ml). Secretin induced test at
15 min was of 322 ng/ml. VIP and 5-HIAA levels were
normal. The stool exam was negative for bacterial and
parasites.
Abdominal ultrasound revealed a liver mass in the 2
nd and
3
rd segment of a 10 x 8 cm diameter and small bowel
distension. A helical computed tomography scan and a
magnetic resonance imaging confirmed the liver mass
with contrast uptake (Figure 1). The fine-needle aspiration
of the liver mass was informed as metastasis of an
adenocarcinoma.
Upper endoscopy was performed and showed grade B (Los
Angeles classification) esophagitis and gastritis as well as
hypertrophy of the gastric folds and multiple duodenum
ulcers with unspecific biopsy and H. Pylori negative.
Bariumintestinalstudyshowedthesamefindings,without
any small bowel lesions.
The gammagraphy with 111 In-DTPA octreotide showed
pathologic uptake in the upper abdomen, especially at the
jejunum wall, with high expression of serotonin receptors.
A PET study was performed which showed high abnormal
uptake in the liver mass as well as a diffuse uptake into the
axils,smallbowelwallandspleen.Thestudywascompleted
by endoscopic capsule examination which did not reveal
alterations at that level and with a complete colonoscopy
without relevant findings. The echocardiography was
normal.
A left hepatectomy was performed and the pathologic
diagnosis pointed out to a primary neuroendocrine
tumour (carcinoid tumour) with poor mitotic activity
and important necrosis. Inmunohistochemistry, on paraf-
fin-embedded formalin fixed sections of the tumour,
showed positive staining for synaptophysin, chromogra-
nine, enolase, CK7 (Figure. 2a, 2b, 2c, 2d) and negative
staining for CEA (Figure 3A). A moderate staining was
detected for gastrin (Figure 3B).
During the follow up, the patient referred total disap-
pearance of the initial clinical symptoms. Upper endo-
scopy revealed no duodenum ulcers and his serum gastrin
levels decreased till 19 pg/ml two months after surgery.
The patient remained free of symptoms two years after
surgery.
Discussion
We report here a case of a primary hepatic carcinoid
tumour (PHCT) associated with a Zollinger Ellison
syndrome. The primary hepatic carcinoid tumours are
uncommon [3] and represent an intriguing diagnosis to
solve. The demonstration of the hepatic origin of a
neuroendocrine tumour is difficult since the liver is a
frequent site for metastases of different types of tumours:
intestinal carcinoids, primary tumours (hepatocarcinoma,
etc)andbenignpathology(nodularfocalhyperplasia,etc).
Carcinoid tumours have their origin in neuroendocrine
stem cells (known as enterochromaffin cells or APUD cells
(Amine Precursor Uptake Decarboxilase) derived from the
embrionary neuronal crest. Cells that migrated from the
neuronal crest can give rise to gastrointestinal carcinoid
Figure 1. Axial section of MRI showing a left lobe liver mass
with central necrosis and contrast uptake.
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common localization the appendix and the small bowel
[4]. Liver has few or none enterochromaffin cells, unlike
other organs (pancreas, for example).
Some theories for the origin of PHCTs have been
proposed. The most accepted thories are: (i) ectopic cells
of pancreatic or adrenal tissue, (ii) neuroectodermal origin
cells, (iii) neuroendocrine programmed ectoblasts [5]. It is
believed that, during the early stages of regeneration, the
bile ducts epithelium displays neuroendocrine character-
istics and cytoplasmatic chromogranin A expression, due
to chronic inflammation [6].
In general, PHCT may vary in size, ranging from 1 cm to
20 cm [7] and their aspect is of a unique mass [3]
completely separated from the surrounding liver tissue.
Females tend to be affected more often than males (1.4:1)
and the age of presentation may range between 18 to 84
years, with an average of 50 years [3,8].
The clinical presentation is atypical, with symptoms
like upper abdominal pain or discomfort like fullness, as
well as diarrhoea or weight loss [3]. Only a small percent
(7%-13%) of patients accuses symptoms of a typical
carcinoid syndrome [3,7].
The radiology diagnosis has poor specificity as the
appearance on ultrasound, CT or MRI is of a solid mass
with cystic areas and hyperechoic or mixed pattern, with
central or peripheral calcifications and fibrous scars. The
majority are intense, hypervascularised tumours, which
explains the contrast enhancement in ultrasound and CT
images, in a similar fashion as the hepatocarcinoma. [9].
When diagnosing a neuroendocrine tumour, an octreoscan
isalways recommendedsince itmay detectsmall metastasic
Figure 2. Immunohistochemical staining of the primary hepatic carcinoid tumour specimen. Positive staining for synaptophysin
(a), chromogranin (b), enolase (c) and cytokeratin 7 (d) in tumour sample and negative in normal liver parenchyma
(synaptophysin, chromogranin, enolase × 400, cytokeratin 7 × 200).
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2 lacking neuroendocrine tumours which are impossible to
detect on somatostatin receptor scintigraphy.
The gold standard for diagnosis is the liver biopsy since it
may differentiate the lesion from other types of tumours.
Cautions must be taken in order to avoid complications
like carcinoid crisis as a recent case report shows [10].
From the histologic point of view the hepatic carcinoma
appears as a hemorrhagic, not capsulated mass, with
central, irregular fibrosis and hyaline degeneration. The
tumoural cells display an eosinophilic cytoplasm and
irregular, hyperchromic nucleus. In inmunohistochemis-
try these cells present a strong positivity for neurosecretory
markers as chromogranin, synaptophysin, neuron specific
enolase meanwhile markers as serotonin, pancreatic
polypeptide or gastrin are inconsistently positive [8].
The treatment is the surgical resection, when possible.
Almost 85% of primary hepatic carcinoid tumour patients
may have a resectable disease [11,12]. Survival and re-
currencetaresfiveyearsaftersurgeryareof80-92.5%[8,13]
and 18% respectively [14]. When a not well defined lesion
is observed, a palliative cyto-reductive surgery in combina-
tion with transcatheter arterial embolization (TACE) and
subsequent administration of lanreotide (long acting
somatostatin analogue) might be effective, as Touloumis
et al. showed recently [12].
In our patient’s case, the immunohistochemistry result
corresponded to a type A carcinoid tumour (APUDOMA).
The moderate staining for gastrin pointed to gastrin
secreting PHCT, associated thus with a Zollinger Ellison
syndrome. In a recent review, gastrin was the most
common hormone secreted of all cases (7/69) of primary
hepatic carcinoid published till date [3].
Primary hepatic carcinoid tumours are rare entities that
sometimes may be associated with syndromes like ZES,
carcinoid, etc. induced by neuroendocrine hormones
secretion (gastrin, 5-HIAA, ACTH; etc). An early and
pertinent diagnosis offers the possibility of surgery resec-
tion, with a good 5 early survival rate and a poor relapse
rate.
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Figure 3. Immunohistochemical staining of the primary
hepatic carcinoid tumour specimen. Panel (a) negative CEA
staining in tumour sample and positive in normal liver
parenchyma (CEA, × 200). Panel (b) moderate gastrin
staining in tumour sample (gastrin, × 400).
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